Evercore ISI analyst Vijay Kumar maintained a Buy rating on Twist Bioscience today and set a price target of $42.00. The company’s shares closed yesterday at $31.85.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Kumar is a 3-star analyst with an average return of 1.3% and a 49.45% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Agilent, Edwards Lifesciences, and Exact Sciences.
In addition to Evercore ISI, Twist Bioscience also received a Buy from Barclays’s Luke Sergott in a report issued on October 2. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Twist Bioscience (NASDAQ: TWST).
Based on Twist Bioscience’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $96.06 million and a net profit of $20.39 million. In comparison, last year the company earned a revenue of $81.46 million and had a GAAP net loss of $85.57 million
Read More on TWST:
Disclaimer & DisclosureReport an Issue
- Twist Bioscience price target lowered to $40 from $45 at Barclays
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks
- Cathie Wood’s ARK Investment buys 221.7K shares of Twist Bioscience today
- PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
- Cathie Wood’s ARK Investment buys 47.7K shares of Twist Bioscience today
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)